RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial

Completed · Phase 3

Conditions studied: Atrial Fibrillation

In brief

The purposes of this study are: 1. To evaluate the long-term safety of dabigatran etexilate 2. To assess the effect of a knowledge translation intervention on patient outcomes

Key facts

Study ID

NCT00808067

Run by

Boehringer Ingelheim

People needed

5897

Starts

2008-11-01

Expected to finish

2012-12-01

Last updated by the study team

2014-06-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participation in RE-LY, requires long term anticoagulation, provides written informed consent

You may not qualify if…

• Permanent discontinuation of dabigatran during RE-LY

Where it is running

• 1160.71.0057 Boehringer Ingelheim Investigational Site — Birmingham, Alabama, United States
• 1160.71.0211 Boehringer Ingelheim Investigational Site — Birmingham, Alabama, United States
• 1160.71.0115 Boehringer Ingelheim Investigational Site — Mobile, Alabama, United States
• 1160.71.0104 Boehringer Ingelheim Investigational Site — Lake Havasu City, Arizona, United States
• 1160.71.0185 Boehringer Ingelheim Investigational Site — Tucson, Arizona, United States
• 1160.71.0038 Boehringer Ingelheim Investigational Site — Hot Springs, Arkansas, United States
• 1160.71.0302 Boehringer Ingelheim Investigational Site — Jonesboro, Arkansas, United States
• 1160.71.0191 Boehringer Ingelheim Investigational Site — Little Rock, Arkansas, United States
• 1160.71.0213 Boehringer Ingelheim Investigational Site — Little Rock, Arkansas, United States
• 1160.71.0441 Boehringer Ingelheim Investigational Site — Carmichael, California, United States
• 1160.71.0333 Boehringer Ingelheim Investigational Site — Fullerton, California, United States
• 1160.71.0384 Boehringer Ingelheim Investigational Site — La Jolla, California, United States
• 1160.71.0246 Boehringer Ingelheim Investigational Site — Lancaster, California, United States
• 1160.71.0070 Boehringer Ingelheim Investigational Site — Merced, California, United States
• 1160.71.0349 Boehringer Ingelheim Investigational Site — Oakland, California, United States
• 1160.71.0016 Boehringer Ingelheim Investigational Site — Oceanside, California, United States
• 1160.71.0459 Boehringer Ingelheim Investigational Site — Pasadena, California, United States
• 1160.71.0270 Boehringer Ingelheim Investigational Site — Poway, California, United States
• 1160.71.0135 Boehringer Ingelheim Investigational Site — Riverside, California, United States
• 1160.71.0300 Boehringer Ingelheim Investigational Site — Sacramento, California, United States
• 1160.71.0284 Boehringer Ingelheim Investigational Site — San Diego, California, United States
• 1160.71.0379 Boehringer Ingelheim Investigational Site — Walnut Creek, California, United States
• 1160.71.0321 Boehringer Ingelheim Investigational Site — Colorado Springs, Colorado, United States
• 1160.71.0449 Boehringer Ingelheim Investigational Site — Colorado Springs, Colorado, United States
• 1160.71.0046 Boehringer Ingelheim Investigational Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.